Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Drugmakers race to find a place in the next wave of obesity drugs
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side Effects
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
Zealand Pharma shares drop 20% as obesity drug side effects raise concerns
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
Zealand Pharma to accelerate drug development for obesity, metabolic disease
Zealand Pharma scraps obesity drug candidate, citing crowded market, Bloomberg News reports
Zealand Pharma may sell future obesity drug direct to patients, amid market shifts
Zealand Pharma Obesity Therapy Shows Positive Trial Results
Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
Zealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetes
Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche
Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate
Roche to develop, commercialize obesity drug with Zealand Pharma
Zealand Pharma CEO says Novo's CagriSema data supports monotherapy approach to cagrilintide
US FDA declines to approve Zealand Pharma's bowel disease drug
Zealand Pharma starts Phase 2b trial for obesity drug candidate petrelintide
Zealand Pharma to start phase 2b trial for obesity drug candidate in Q4
Wegovy and Zepbound rival targeting 'next generation' of obesity drugs, Zealand Pharma CEO says